JP2011162558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011162558A5 JP2011162558A5 JP2011110047A JP2011110047A JP2011162558A5 JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5 JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- galnac4st
- c6st
- test compound
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001519 tissue Anatomy 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 230000014509 gene expression Effects 0.000 claims 5
- 102100032146 Carbohydrate sulfotransferase 11 Human genes 0.000 claims 4
- 101710096631 Carbohydrate sulfotransferase 11 Proteins 0.000 claims 4
- 102100038768 Carbohydrate sulfotransferase 3 Human genes 0.000 claims 4
- 101710158430 Carbohydrate sulfotransferase 3 Proteins 0.000 claims 4
- 102100038780 Carbohydrate sulfotransferase 7 Human genes 0.000 claims 4
- 101710158444 Carbohydrate sulfotransferase 7 Proteins 0.000 claims 4
- 102100031276 Carbohydrate sulfotransferase 8 Human genes 0.000 claims 4
- 101710158439 Carbohydrate sulfotransferase 8 Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 102100033377 Carbohydrate sulfotransferase 15 Human genes 0.000 claims 3
- 102100032144 Carbohydrate sulfotransferase 9 Human genes 0.000 claims 3
- 101710158443 Carbohydrate sulfotransferase 9 Proteins 0.000 claims 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 3
- 108010028286 N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase Proteins 0.000 claims 3
- 108700008625 Reporter Genes Proteins 0.000 claims 3
- 102000004896 Sulfotransferases Human genes 0.000 claims 2
- 108090001033 Sulfotransferases Proteins 0.000 claims 2
- 102000004357 Transferases Human genes 0.000 claims 2
- 108090000992 Transferases Proteins 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000002808 connective tissue Anatomy 0.000 claims 2
- 210000003792 cranial nerve Anatomy 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000005003 heart tissue Anatomy 0.000 claims 2
- 210000005228 liver tissue Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000004923 pancreatic tissue Anatomy 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- -1 GalNAc4ST -B Proteins 0.000 claims 1
- WHCJUIFHMJFEFZ-UIAUGNHASA-N N-acetyl-beta-D-galactosamine 4-sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O WHCJUIFHMJFEFZ-UIAUGNHASA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011110047A JP5481426B2 (ja) | 2007-12-27 | 2011-05-17 | 糖鎖関連遺伝子、およびその利用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007336518 | 2007-12-27 | ||
| JP2007336518 | 2007-12-27 | ||
| JP2011110047A JP5481426B2 (ja) | 2007-12-27 | 2011-05-17 | 糖鎖関連遺伝子、およびその利用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010173610A Division JP4751956B2 (ja) | 2007-12-27 | 2010-08-02 | 糖鎖関連遺伝子、およびその利用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011162558A JP2011162558A (ja) | 2011-08-25 |
| JP2011162558A5 true JP2011162558A5 (enExample) | 2013-02-14 |
| JP5481426B2 JP5481426B2 (ja) | 2014-04-23 |
Family
ID=40823968
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547912A Active JP4585611B2 (ja) | 2007-12-27 | 2008-12-26 | 糖鎖関連遺伝子、およびその利用 |
| JP2010173610A Active JP4751956B2 (ja) | 2007-12-27 | 2010-08-02 | 糖鎖関連遺伝子、およびその利用 |
| JP2011110047A Active JP5481426B2 (ja) | 2007-12-27 | 2011-05-17 | 糖鎖関連遺伝子、およびその利用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547912A Active JP4585611B2 (ja) | 2007-12-27 | 2008-12-26 | 糖鎖関連遺伝子、およびその利用 |
| JP2010173610A Active JP4751956B2 (ja) | 2007-12-27 | 2010-08-02 | 糖鎖関連遺伝子、およびその利用 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20110027248A1 (enExample) |
| EP (4) | EP3673910B1 (enExample) |
| JP (3) | JP4585611B2 (enExample) |
| KR (6) | KR20100111282A (enExample) |
| CN (2) | CN101965196A (enExample) |
| SG (2) | SG10202001748VA (enExample) |
| WO (1) | WO2009084232A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5547964B2 (ja) * | 2007-06-29 | 2014-07-16 | 株式会社ステリック再生医科学研究所 | 生理活性物質を定着および発現させる方法 |
| PL2460403T3 (pl) | 2009-07-31 | 2019-11-29 | Smc Global Asset Inc | Mysi model stłuszczeniowego zapalenia wątroby-raka wątroby |
| US20140323550A1 (en) | 2011-11-18 | 2014-10-30 | Nitto Denko Corporation | Intestinal fibrosis treatment agent |
| EP3693462A1 (en) * | 2012-07-17 | 2020-08-12 | Stelic Institute&Co. | Mucosal healing promoter |
| KR102482890B1 (ko) * | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| JP6302183B2 (ja) * | 2013-07-12 | 2018-03-28 | 株式会社エンザミン研究所 | アディポサイトカイン産生バランス調整剤及び脂肪組織の炎症・酸化ストレス抑制剤並びに脂肪組織のマクロファージ浸潤抑制剤 |
| US9932599B2 (en) | 2015-03-02 | 2018-04-03 | Synthetic Genomics, Inc. | Regulatory elements from labyrinthulomycetes microorganisms |
| JPWO2017078054A1 (ja) | 2015-11-04 | 2018-08-30 | 株式会社ステリック再生医科学研究所 | ＲＮＡｉ分子とＮ−アセチル化キトサンとを含む複合体 |
| US10633454B2 (en) | 2016-11-01 | 2020-04-28 | Conagen Inc. | Expression of modified glycoproteins and glycopeptides |
| EP3551047A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3552632B1 (en) | 2016-12-07 | 2023-07-12 | Stelic Institute & Co., Inc. | Medicinal composition for treating and preventing inflammatory bowel disease |
| WO2018183934A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
| WO2019173226A1 (en) * | 2018-03-05 | 2019-09-12 | Synthetic Genomics, Inc. | Organisms and methods for producing glycomolecules with low sulfation |
| CN109897812B (zh) * | 2019-03-19 | 2021-09-03 | 江南大学 | 一种表达软骨素4-硫酸转移酶基因的重组菌及其应用 |
| US20220184110A1 (en) * | 2019-05-08 | 2022-06-16 | Tme Therapeutics Inc. | Esophageal stricture suppressing agent |
| CN116254296A (zh) * | 2023-03-27 | 2023-06-13 | 中国科学院微生物研究所 | 利用昆虫细胞杆状病毒表达系统表达硫酸软骨素修饰酶的方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4571242B2 (ja) * | 1996-07-24 | 2010-10-27 | 生化学工業株式会社 | ヒト由来のグリコサミノグリカンスルホトランスフェラーゼのポリペプチド及びそれをコードするｄｎａ |
| CA2285940A1 (en) * | 1997-04-11 | 1998-10-22 | K. Ramakrishnan Bhaskar | Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions |
| EP1839671A3 (en) * | 1999-12-02 | 2007-10-31 | BioMarin Pharmaceutical Inc. | Attenuation of fibroblast proliferation |
| WO2001039795A2 (en) * | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
| US6713274B2 (en) | 2002-05-13 | 2004-03-30 | The Regents Of The University Of California | Method for identifying modulators of sulfotransferase activity |
| AU2003252593A1 (en) * | 2002-07-10 | 2004-02-02 | Seikagaku Corporation | Sulfotransferase inhibitors |
| PT1734970E (pt) * | 2004-03-12 | 2015-03-11 | Intercept Pharmaceuticals Inc | Tratamento de fibrose utilizando ligandos de rfx |
| WO2007049361A1 (ja) * | 2005-10-27 | 2007-05-03 | Stelic Corp. | 肝線維化抑制剤 |
| JP2009286695A (ja) * | 2006-09-08 | 2009-12-10 | Stelic Institute Of Regenerative Medicine | 眼線維性血管新生抑制剤 |
| US20090202515A1 (en) * | 2006-09-08 | 2009-08-13 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Agents for suppressing neural fibrotic degeneration |
| JP5547964B2 (ja) * | 2007-06-29 | 2014-07-16 | 株式会社ステリック再生医科学研究所 | 生理活性物質を定着および発現させる方法 |
-
2008
- 2008-12-26 JP JP2009547912A patent/JP4585611B2/ja active Active
- 2008-12-26 SG SG10202001748VA patent/SG10202001748VA/en unknown
- 2008-12-26 EP EP20151386.8A patent/EP3673910B1/en active Active
- 2008-12-26 KR KR1020107016694A patent/KR20100111282A/ko not_active Ceased
- 2008-12-26 KR KR1020197037818A patent/KR102244872B1/ko active Active
- 2008-12-26 WO PCT/JP2008/004025 patent/WO2009084232A1/ja not_active Ceased
- 2008-12-26 KR KR1020157037089A patent/KR20160007671A/ko not_active Withdrawn
- 2008-12-26 US US12/809,969 patent/US20110027248A1/en not_active Abandoned
- 2008-12-26 EP EP15194114.3A patent/EP3045178A1/en not_active Withdrawn
- 2008-12-26 CN CN200880127570XA patent/CN101965196A/zh active Pending
- 2008-12-26 CN CN201310495268.2A patent/CN103656644A/zh active Pending
- 2008-12-26 EP EP08866254A patent/EP2238987A4/en not_active Withdrawn
- 2008-12-26 KR KR1020177023558A patent/KR101926292B1/ko active Active
- 2008-12-26 SG SG10201402793PA patent/SG10201402793PA/en unknown
- 2008-12-26 KR KR1020167022756A patent/KR20160103554A/ko not_active Ceased
- 2008-12-26 KR KR1020187034630A patent/KR20180132162A/ko not_active Ceased
- 2008-12-26 EP EP18151424.1A patent/EP3360556B1/en active Active
-
2010
- 2010-08-02 JP JP2010173610A patent/JP4751956B2/ja active Active
-
2011
- 2011-05-17 JP JP2011110047A patent/JP5481426B2/ja active Active
-
2013
- 2013-11-08 US US14/075,919 patent/US20140128452A1/en not_active Abandoned
-
2015
- 2015-05-05 US US14/704,333 patent/US20150290238A1/en not_active Abandoned
-
2016
- 2016-07-21 US US15/216,231 patent/US20170067058A1/en not_active Abandoned
-
2019
- 2019-01-02 US US16/237,875 patent/US20190330637A1/en not_active Abandoned
-
2022
- 2022-06-03 US US17/805,290 patent/US20220340910A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011162558A5 (enExample) | ||
| JP2011037847A5 (enExample) | ||
| AU2018253580A1 (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| HK1199068A1 (en) | Identification of gene expression profile as a predictive biomarker for lkb1 status | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| JP2012050449A5 (enExample) | ||
| BR112014015202A8 (pt) | processo para a melhor separação de uma solução orgânica hidrófoba de um meio de cultura aquoso | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof | |
| JP2009178558A5 (enExample) | ||
| EA201401353A1 (ru) | Биомаркеры для определения эффективной ответной реакции на лечение пациентов с гепатоцеллюлярной карциномой (гцк) | |
| JP2016528914A5 (enExample) | ||
| MX357507B (es) | Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato. | |
| JP2013527772A5 (enExample) | ||
| Huang et al. | Circulating cell-free DNA levels correlate with postresuscitation survival rates in out-of-hospital cardiac arrest patients | |
| WO2013141705A3 (en) | Means and methods for response prediction of hepatitis b treatment | |
| WO2012078648A3 (en) | Novel method of cancer diagnosis and prognosis and prediction of response to therapy | |
| JP2017513515A5 (enExample) | ||
| PH12014502282A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
| WO2008008487A3 (en) | Gene expression profiling for identification, monitoring and treatment of multiple sclerosis | |
| TN2012000607A1 (en) | Method for predicting a therapy response in subjects with multiple sclerosis | |
| RU2009145864A (ru) | Способ прогнозирования дизадаптации сердечной деятельности у детей, перенесших кардиохирургическую коррекцию врожденного порока сердца | |
| PH12019500738A1 (en) | Methods of preserving the biological activity of ribonucleic acids | |
| RU2017139718A (ru) | Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток | |
| WO2008085921A3 (en) | Methods for reduction of adipose tissue mass | |
| Subbotina | Renal Sympathetic Denervation. Quality of Life, Hypertensive Heart Disease and Biomarker Discovery |